Danmark - dansk - SEGES Landbrug & Fødevarer

arysta lifescience benelux sprl (tidl.: agriphar s.a.) - mechlorprop-p, dicamba, mcpa, 2,4-d - flydende middel - 0,46 g/l mechlorprop-p ; 0,23 g/l dicamba ; 0,7 g/l mcpa ; 0,7 g/l 2,4-d

Danmark - dansk - SEGES Landbrug & Fødevarer

arysta lifescience benelux sprl (tidl.: agriphar s.a.) - mechlorprop-p, dicamba, mcpa, 2,4-d - flydende middel - 0,46 g/l mechlorprop-p ; 0,23 g/l dicamba ; 0,7 g/l mcpa ; 0,7 g/l 2,4-d

Danmark - dansk - SEGES Landbrug & Fødevarer

arysta lifescience benelux sprl (tidl.: agriphar s.a.) - mechlorprop-p, dicamba, mcpa, 2,4-d - flydende middel - 0,46 g/l mechlorprop-p ; 0,23 g/l dicamba ; 0,7 g/l mcpa ; 0,7 g/l 2,4-d

Danmark - dansk - SEGES Landbrug & Fødevarer

arysta lifescience benelux sprl (tidl.: agriphar s.a.) - mechlorprop-p, dicamba, mcpa, 2,4-d - flydende middel - 0,46 g/l mechlorprop-p ; 0,23 g/l dicamba ; 0,7 g/l mcpa ; 0,7 g/l 2,4-d

Danmark - dansk - SEGES Landbrug & Fødevarer

arysta lifescience benelux sprl (tidl.: agriphar s.a.) - mechlorprop-p, dicamba, mcpa, 2,4-d - flydende middel - 0,46 g/l mechlorprop-p ; 0,23 g/l dicamba ; 0,7 g/l mcpa ; 0,7 g/l 2,4-d

Danmark - dansk - SEGES Landbrug & Fødevarer

arysta lifescience benelux sprl (tidl.: agriphar s.a.) - cypermethrin - flydende middel - 20 g/l cypermethrin

Danmark - dansk - SEGES Landbrug & Fødevarer

arysta lifescience benelux sprl (tidl.: agriphar s.a.) - chlorpropham - flydende middel - 500 g/l chlorpropham

Den Europæiske Union - dansk - EMA (European Medicines Agency)

ecuphar - hydrocortisonacceponat - corticosteroider, dermatologiske præparater - hunde - til symptomatisk behandling af inflammatoriske og pruritiske dermatoser hos hunde. for alleviation of clinical signs associated with atopic dermatitis in dogs.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

koanaa healthcare gmbh - imatinib mesilate - leukemia, myelogenous, chronic, bcr-abl positive; precursor cell lymphoblastic leukemia-lymphoma; myelodysplastic-myeloproliferative diseases; hypereosinophilic syndrome; dermatofibrosarcoma; gastrointestinal stromal tumors - antineoplastiske midler - imatinib koanaa is indicated for the treatment ofadult and paediatric patients with newly diagnosed philadelphia chromosome (bcr-abl) positive (ph+) chronic myeloid leukaemia (cml) for whom bone marrow transplantation is not considered as the first line of treatment. adult and paediatric patients with ph+ cml in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis. adult and paediatric patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) integrated with chemotherapy. adult patients with relapsed or refractory ph+ all as monotherapy. adult patients with myelodysplastic/myeloproliferative diseases (mds/mpd) associated with platelet-derived growth factor receptor (pdgfr) gene re-arrangements. adult patients with advanced hypereosinophilic syndrome (hes) and/or chronic eosinophilic leukaemia (cel) with fip1l1-pdgfrα rearrangement. the effect of imatinib on the outcome of bone marrow transplantation has not been determined. imatinib koanaa is indicated forthe treatment of adult patients with kit (cd 117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (gist). the adjuvant treatment of adult patients who are at significant risk of relapse following resection of kit (cd117)-positive gist. patienter, der har en lav eller meget lav risiko for tilbagefald, bør ikke modtage adjuverende behandling. the treatment of adult patients with unresectable dermatofibrosarcoma protuberans (dfsp) and adult patients with recurrent and/or metastatic dfsp who are not eligible for surgery. in adult and paediatric patients, the effectiveness of imatinib is based on overall haematological and cytogenetic response rates and progression-free survival in cml, on haematological and cytogenetic response rates in ph+ all, mds/mpd, on haematological response rates in hes/cel and on objective response rates in adult patients with unresectable and/or metastatic gist and dfsp and on recurrence-free survival in adjuvant gist. the experience with imatinib in patients with mds/mpd associated with pdgfr gene re-arrangements is very limited (see section 5. undtagen i nyligt diagnosticeret kronisk cml-fase, der er ingen kontrollerede undersøgelser, der påviser en klinisk fordel eller øget overlevelse for disse sygdomme.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

esteve pharmaceuticals gmbh - ziconotid - injections, spinal; pain - analgetika - ziconotid er indiceret til behandling af alvorlig kronisk smerte hos patienter, som har brug for intratekal (it) analgesi.